Osteodex

DRUG4 trials

Sponsors

Dextech Medical AB, DexTech Medical AB

Conditions

Multiple MyelomaProstate Cancer Metastatic

Phase 1

A Phase I/II Study of ODX (Osteodex) in Metastatic Castration Resistant Prostate Cancer (CRPC)

CompletedNCT01595087

DexTech Medical ABProstate Cancer Metastatic

Start: 2012-01-31End: 2013-09-30Updated: 2014-11-14

A Phase I/IIa Study of ODX (OsteoDex) in Multiple Myeloma

Not yet recruitingCTIS2024-516969-36-00

Dextech Medical ABMultiple Myeloma

Target: 12Updated: 2025-10-06

Phase 2

A Phase IIb Study to Evaluate Efficacy and Tolerability of ODX (Osteodex) in Metastatic CRPC

TerminatedNCT02378870

DexTech Medical ABProstate Cancer Metastatic

Start: 2015-01-31End: 2015-09-30Updated: 2016-06-30

Study of ODX (Osteodex) in Metastatic Castration Resistant Prostate Cancer (CRPC)

CompletedNCT02825628

DexTech Medical ABProstate Cancer Metastatic

Start: 2016-05-31End: 2020-06-30Updated: 2024-08-29

Related Papers

A randomised, double-blind, dose-finding, phase II multicentre study of ODX in the treatment of patients with castration-resistant prostate cancer and skeletal metastases

European Journal of Cancer2022-12-195 citations

Efficacy of a novel cytotoxic polybisphosphonate for treatment of bone metastasis in castration-resistant prostate cancer (CRPC).

Journal of Clinical Oncology2015-05-20

Efficacy of a novel cytotoxic polybisphosphonate for treatment of bone metastasis in castration-resistant prostate cancer (CRPC).

Journal of Clinical Oncology2015-03-01